Funding for cancer test
BC has become the latest province to fund a test that can help determine whether patients with a certain type of early stage breast cancer could benefit from chemotherapy.
California-based Genomic Health says the BC Cancer Agency has agreed to fund the company's Oncotype DX test.
The test, which costs US$4,300, examines genes within breast cancer tumours to predict which patients would benefit from chemotherapy.
Conversely, the test is also used to predict which patients would see little or no benefit from chemotherapy.
The funding applies to patients that meet a list of criteria, including that they have early stage, node-negative, estrogen receptor-positive invasive breast cancer.
The test is already funded by provincial governments in Alberta, Ontario, Quebec, Saskatchewan, and Newfoundland and Labrador.
Comments on this story are pre-moderated. Before they appear, comments are reviewed by moderators to ensure they meet our submission guidelines. Keep it clean, keep it civil, keep it truthful, stay on topic and be responsible. Comments are open and welcome for three days after the story is published. We reserve the right to close comments before then. Comments that appear on the site are not the opinion of Castanet, but only of the comment writer.
Read more BC News
- Tourist falls to his deathPenticton / S. Okanagan
- Hwy 5 partially closedCentral Okanagan
- BC sets up support paymentsBC
- Family looks for answersKelowna